BioCentury | Nov 7, 2020
Product Development

Amgen’s adaptive solution to lupus

...of clinical trial software and services company Cytel...
BioCentury | Jul 6, 1999
Finance

Fair to middling

...setbacks The second quarter was not short on clinical setbacks, which included late-stage hiccups by Cytel Corp....
BioCentury | Jul 6, 1999
Company News

Cytel, Epimmune deal

...June 21). The merged company, Epimmune Inc., will trade on NASDAQ under the symbol EPMN. Cytel Corp....
BioCentury | Jun 21, 1999
Company News

Cytel, Epimmune infectious diseases, cancer news

...Epimmune employees and partner G.D. Searle & Co. (Chicago, Ill.) holding the remaining 33 percent. Cytel Corp....
BioCentury | May 17, 1999
Company News

Cytel other research news

...Epimmune's EIS, which allows for identification and validation of T cell epitopes from gene sequences. Cytel Corp....
BioCentury | May 3, 1999
Company News

Bio-Technology General management update

...Cardiovascular, Metabolic, Ophthalmic Hired: Virgil Thompson as president and COO, formerly president and CEO of Cytel Corp....
BioCentury | May 3, 1999
Company News

Cytel management update

Cytel Corp. (CYTL), San Diego, Calif. Business: Infectious diseases Resigned: Virgil Thompson as president and CEO to become president and COO of Bio-Technology General Corp. while remaining a CYTL director Transition: Robert Roe becomes acting...
BioCentury | Apr 12, 1999
Clinical News

Cytel preclinical data

...from the vaccinated mice protected human cells in vitro from Plasmodium falciparum, the malaria parasite. Cytel Corp....
BioCentury | Apr 12, 1999
Clinical News

Cytel preclinical data

...of Immunology that a PADRE-based vaccine enhanced T lymphocyte function in mice chronically producing HBV. Cytel Corp....
BioCentury | Apr 12, 1999
Finance

Looking for some magic

...Group (LSE:COG) 99.0p 37.5p -62% Corvas (CVAS) $5.000 $2.500 -50% Cubist (CBST) $4.500 $3.125 -31% Cytel...
Items per page:
1 - 10 of 106
BioCentury | Nov 7, 2020
Product Development

Amgen’s adaptive solution to lupus

...of clinical trial software and services company Cytel...
BioCentury | Jul 6, 1999
Finance

Fair to middling

...setbacks The second quarter was not short on clinical setbacks, which included late-stage hiccups by Cytel Corp....
BioCentury | Jul 6, 1999
Company News

Cytel, Epimmune deal

...June 21). The merged company, Epimmune Inc., will trade on NASDAQ under the symbol EPMN. Cytel Corp....
BioCentury | Jun 21, 1999
Company News

Cytel, Epimmune infectious diseases, cancer news

...Epimmune employees and partner G.D. Searle & Co. (Chicago, Ill.) holding the remaining 33 percent. Cytel Corp....
BioCentury | May 17, 1999
Company News

Cytel other research news

...Epimmune's EIS, which allows for identification and validation of T cell epitopes from gene sequences. Cytel Corp....
BioCentury | May 3, 1999
Company News

Bio-Technology General management update

...Cardiovascular, Metabolic, Ophthalmic Hired: Virgil Thompson as president and COO, formerly president and CEO of Cytel Corp....
BioCentury | May 3, 1999
Company News

Cytel management update

Cytel Corp. (CYTL), San Diego, Calif. Business: Infectious diseases Resigned: Virgil Thompson as president and CEO to become president and COO of Bio-Technology General Corp. while remaining a CYTL director Transition: Robert Roe becomes acting...
BioCentury | Apr 12, 1999
Clinical News

Cytel preclinical data

...from the vaccinated mice protected human cells in vitro from Plasmodium falciparum, the malaria parasite. Cytel Corp....
BioCentury | Apr 12, 1999
Clinical News

Cytel preclinical data

...of Immunology that a PADRE-based vaccine enhanced T lymphocyte function in mice chronically producing HBV. Cytel Corp....
BioCentury | Apr 12, 1999
Finance

Looking for some magic

...Group (LSE:COG) 99.0p 37.5p -62% Corvas (CVAS) $5.000 $2.500 -50% Cubist (CBST) $4.500 $3.125 -31% Cytel...
Items per page:
1 - 10 of 106